Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
about
Global research trends of Middle East respiratory syndrome coronavirus: a bibliometric analysisReceptor-binding domain-based subunit vaccines against MERS-CoVCurrent advancements and potential strategies in the development of MERS-CoV vaccinesVaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routesMolecular aspects of MERS-CoV.Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike proteinRNA virus reverse genetics and vaccine design.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseDevelopment of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Evaluation of candidate vaccine approaches for MERS-CoV.Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.An update on Middle East respiratory syndrome: 2 years later.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Vaccines for the prevention against the threat of MERS-CoV.Middle East respiratory syndrome: current status and future prospects for vaccine development.Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.Two deletion variants of Middle East respiratory syndrome coronavirus found in a patient with characteristic symptoms.A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.MERS-CoV: Bridging the Knowledge Gaps.Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach.Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.MERS-CoV: Understanding the Latest Human Coronavirus Threat.A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
P2860
Q24672466-36FECE43-F8D8-4842-AB2C-51EBCD81C07AQ26851979-4AB6A8E0-631B-4444-808D-AE8852CDFFCAQ27012578-231EED98-BE30-4595-93A3-180F23D29B5EQ30096805-1DCFB464-7611-4E0B-9088-69817F175066Q30234479-17B88E9C-8EF2-4E5A-9C0D-3A45151260FDQ30368736-B024438C-9750-40C5-A9E7-038DE627095AQ30371303-06726E30-C288-4A68-9ED9-F31B3EF93C8EQ30378994-AB80AA29-E1F0-4D8B-83A9-DCEAF614412DQ30399700-727699F2-4583-4409-A95B-CFA26DB6CEC3Q30400066-35B50BA5-1D62-4101-AA29-0F917196E521Q30402347-984550A0-B414-48D3-9EE3-519543609446Q33963398-FD1BBC87-CB6B-44D6-842B-93EAA7AB6421Q34324907-4D3F63C4-8A56-4FFE-84BB-78A1B2B8E11AQ34468689-CB413331-0A6A-4016-99AC-67739507DFDBQ35886473-0AC1D1F0-6D09-4947-92DE-5578B9B49010Q35887146-4D9DFBE3-6841-4510-A249-DDBB5EE98E48Q35887626-5F16ED87-8BA3-4CF1-B9C2-A704958A7E52Q35917397-67639B65-DF30-4D44-A0D7-93BDD952B191Q36252666-BD3FD65E-CC34-40DC-AF6D-752E58D764ADQ37512915-6C7164B9-E8FA-450A-A48F-1F6550829242Q37560824-8576EB4D-0E5B-4805-B8B4-D000A6105A01Q38384184-71B7E57D-B36B-4CC7-B37A-ED0BC37FD863Q38461061-C1304847-3BFA-43D5-9D9C-C6AA9428998DQ38778044-2939F533-3B5E-4964-8A41-9816478E9D7DQ38959242-B8421360-C641-41F4-9054-C2AB8FC67C83Q39102732-62D38A29-3396-43A1-B0CD-3DA423C97C42Q39607762-8B1D4023-7301-4864-834F-B759FB5A91D3Q40503787-1A7DA1B9-1DC1-4779-A74B-A3945AA7A9C7Q40541985-0B5AA430-F6FE-448F-B5F1-202877FA7232Q41242033-675E0EC8-4BC0-49E4-AD62-12900E19C12CQ41754327-6263615E-3C7F-4085-A983-1099BC3AAA7EQ47607374-FFF66596-E4AD-4BD6-B567-3FD124EB65E4Q53701486-105F407C-982F-4C07-848F-A9DE3CA28199Q58693121-13AF0641-F735-4842-86F9-1C75827EB27D
P2860
Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@ast
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@en
type
label
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@ast
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@en
prefLabel
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@ast
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@en
P2093
P2860
P1433
P1476
Intranasal vaccination with re ...... g novel mucosal MERS vaccines.
@en
P2093
Chien-Te K Tseng
Cuiqing Ma
Guangyu Zhao
Xinrong Tao
Yusen Zhou
P2860
P304
P356
10.1016/J.VACCINE.2014.02.004
P407
P577
2014-02-18T00:00:00Z